CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 728 enrolled
Drug / intervention
Calcifediol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05819918
NCT05819918N/ACompleted
CompareCT.gov

Calcifediol in the Treatment of COVID 19. Modification of Therapeutic Response by Best Available Treatment or Other Treatment or Clinical Variables

Maimónides Biomedical Research Institute of Córdoba·observational·Posted Apr 19, 2023·Updated Apr 28, 2023

In Brief

An observational study evaluating Calcifediol and Best available therapy for COVID-19. Completed, enrolled 728 participants across 1 site.

Detailed Summary

Patients hospitalized with COVID-19 treated with calcifediol during the first outbreaks of the pandemic (until the first vaccinations) are compared with the aim of determining the therapeutic, clinical, functional, and biochemical variables that modify the response (admission to ICU or death) to calcifediol during hospitalization for COVID 19

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 19, 2023
Enrollment StartApr 1, 2022
Primary CompletionApr 17, 2023
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.2 years ago

Interventions

Calcifedioldrug

Subjects hospitalized with COVID-19 treated with calcifediol

Best available therapydrug

Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.